ChemMedChem · 2018 · 27 citations · 27 references
MedicineMedicinal ChemistryPharmacologyCell SignalingDrug DiscoverySignal TransductionLigand BindingReceptor BindingReceptor Tyrosine Kinase SignalingReceptor-ligand InteractionsTyrosine Kinase InhibitorsCell MorphologyEph Receptor SignalingExtracellular DomainsMolecular ReceptorsReceptor-ligand Selectivity
Erythropoietin-producing hepatocellular (EPH) receptors are transmembrane receptor tyrosine kinases. Their extracellular domains bind specifically to ephrin A/B ligands, and this binding modulates intracellular kinase activity. EPHs are key players in bidirectional intercellular signaling, controlling cell morphology, adhesion, and migration. They are increasingly recognized as cancer drug targets. We analyzed the binding of NVP-BHG712 (NVP) to EPHA2 and EPHB4. Unexpectedly, all tested commercially available NVP samples turned out to be a regioisomer (NVPiso) of the inhibitor, initially described in a Novartis patent application. They only differ by the localization of a single methyl group on either one of two adjacent nitrogen atoms. The two compounds of identical mass revealed different binding modes. Furthermore, both in vitro and in vivo experiments showed that the isomers differ in their kinase affinity and selectivity.
27
The target landscape of clinical kinase drugs
Susan Klaeger, Stephanie Heinzlmeir, Mathias Wilhelm et al. · Science · 2017 · 871 citations · Full text
Medicine, Oncology, Pharmacology +15
MicroScale Thermophoresis: Interaction analysis and beyond
Moran Jerabek‐Willemsen, Timon André, Randy Wanner et al. · Journal of Molecular Structure · 2014 · 704 citations · Full text
EphA2 overexpression causes tumorigenesis of mammary epithelial cells.
Daniel P. Zelinski, Nicole D. Zantek, Jane C. Stewart et al. · PubMed · 2001 · 463 citations
Medicine, Cancer Biology, Oncology +17